<DOC>
	<DOCNO>NCT00040443</DOCNO>
	<brief_summary>Glutamate fundamentally involve learning memory . Memory loss associate mild cognitive impairment may due loss glutamate receptor age brain . There evidence CX516 enhance brain activity specifically target remain glutamate receptor affect portion brain . This study test safety efficacy CX516 symptomatic treatment participant mild cognitive impairment .</brief_summary>
	<brief_title>Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment .</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Inclusion criterion Clinical diagnosis mild cognitive impairment Good general health additional disease would interfere study . Exclusion criteria Any significant neurologic disease ( suspected incipient Alzheimer 's disease ) , Parkinson 's disease , stroke , TIA 's , multiinfarct dementia , Huntington 's disease , head trauma , chronic CNS infection . History major depression another major psychiatric disorder within past 6 month . History schizophrenia , mania recurrent psychotic episode . History alcohol DSM IVdiagnosed substance abuse dependence disorder within past year . History blackout , epilepsy seizure , abnormal EEG judge Investigator consider age participant . Any clinically significant hepatic , renal , cardiovascular , pulmonary , gastrointestinal hematological illness unstable medical condition could interfere drug safety , absorption , distribution , metabolism excretion , lead difficulty comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Memory Loss</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Brain Aging</keyword>
	<keyword>AmpalexÂ®</keyword>
	<keyword>CX516</keyword>
</DOC>